Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

A user shared their positive experience with hair regrowth using finasteride 1.25 mg daily and dermastamping every two weeks. They reported no side effects and noticed regrowth after about three months.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A 42-year-old user shared progress after 6 months using 1.25mg finasteride and 5mg oral minoxidil daily, with 5% topical minoxidil twice a day, improved nutrition, and weekly dermarolling. The user noticed some shedding and slower regrowth but remains disciplined, while others commented on the impressive results and potential side effects of high minoxidil doses.

A 30-year-old MTF individual shared a 6-month update on hair loss improvement using minoxidil, retinol, and microneedling, along with lowering testosterone to reduce DHT. They reported positive results, feeling happier and more confident.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.

The user reports improved hair condition after 6 months of oral finasteride and 3 months of topical minoxidil, using a q-tip for application, and incorporating Nizoral shampoo and weekly natural oil treatments. Commenters are impressed with the positive results on the user's hairline.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The user experienced significant hair darkening and progress in hair regrowth over six months using 5% topical minoxidil, 5 mg oral minoxidil, 1 mg finasteride, and weekly microneedling. No side effects were reported from these treatments.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

A 26-year-old male shared progress pictures after 4 months of treating hair loss with finasteride (1.25 mg on Mondays, Wednesdays, and Fridays), topical minoxidil twice daily, ketoconazole shampoo twice weekly, and weekly microneedling at 1.5 mm. He is seeing hair growth improvement, especially in the front, and is considering hair grafts for the crown area if necessary for more density.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

User shared 6-month progress using Fin, Min, Microneedling, Biotin, and Ketoconazole Shampoo for hair loss. They microneedle once a week, use 1.25 mg Fin daily, and apply topical Min twice a day.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation is about a user's 26-month hair loss treatment journey using finasteride, minoxidil foam, and microneedling, with gradual improvement in their hairline. The user applied treatments consistently and adjusted the frequency of microneedling based on feedback, noting that progress can feel slow compared to others.